Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966967 | 0.96 | ALDH1A1 (0.53) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1965820 | 0.78 | NR1H4 (0.55) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1967263 | 0.78 | ALDH1A1 (0.42) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27528793 | 0.78 | ALDH1A1 (0.51) | ALDH1A1KDM4EATMNPC1RAB9A | |
| SCHEMBL13464363 | 0.77 | KDM4E (0.53) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1967026 | 0.77 | ATM (0.46) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13464263 | 0.75 | ATM (0.52) | ALDH1A1ATMNPC1RAB9AHTT | |
| SCHEMBL2991130 | 0.75 | KDM4E (0.63) | ALDH1A1KDM4EATMNPC1RAB9A | |
| SCHEMBL6747493 | 0.75 | ATM (0.65) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1967987 | 0.74 | KDM4E (0.50) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334675-B1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2014-03-26 | — | — | EP | claimed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | claimed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | claimed |
| EP-2334675-B1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2014-03-26 | — | — | EP | disclosed |
| EP-2334675-B1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2014-03-26 | — | — | EP | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| EP-2334675-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010032195-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010032195-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | TYMP, IMPDH1, DPYD | ALDH1A1 203/4885KDM4E 1975/4885CYP1A2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.